MARKET

ANIP

ANIP

ANI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.22
+0.32
+0.97%
Closed 16:00 05/11 EDT
OPEN
32.53
PREV CLOSE
32.90
HIGH
34.11
LOW
31.04
VOLUME
111.56K
TURNOVER
--
52 WEEK HIGH
40.00
52 WEEK LOW
23.55
MARKET CAP
423.22M
P/E (TTM)
-17.6439
1D
5D
1M
3M
1Y
5Y
Raymond James Maintains Outperform on ANI Pharmaceuticals, Raises Price Target to $60
Raymond James analyst Elliot Wilbur maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Outperform and raises the price target from $40 to $60.
Benzinga · 1d ago
DJ ANI Pharmaceuticals Is Maintained at Outperform by Raymond James
Dow Jones · 1d ago
DJ ANI Pharmaceuticals Price Target Raised to $60.00/Share From $40.00 by Raymond James
Dow Jones · 1d ago
--Raymond James Adjusts Price Target on ANI Pharmaceuticals to $60 From $40, Maintains Outperform Rating
MT Newswires · 1d ago
Polyalkylene Glycol Market Size Forecast to Reach $18 Billion by 2026
May 07, 2021 (AB Digital via COMTEX) -- Polyalkylene Glycol Market is forecast to reach $18 billion by 2026, after growing at a CAGR of 9.5% during...
ABNewswire · 4d ago
DJ ANI Pharmaceuticals, Inc. CEO Nikhil Lalwani on Q1 2021 Results -- Earnings Call Transcript >ANIP
Dow Jones · 4d ago
8-K: ANI PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- 0001023024 false 0001023024 2021-05-07 2021-05-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
10-Q: ANI PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following Management's...
Edgar Online - (EDG = 10Q, 10K) · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANIP. Analyze the recent business situations of ANI Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANIP stock price target is 45.00 with a high estimate of 60.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 245
Institutional Holdings: 8.86M
% Owned: 69.51%
Shares Outstanding: 12.74M
TypeInstitutionsShares
Increased
39
427.48K
New
17
314.09K
Decreased
42
260.25K
Sold Out
14
374.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.55%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Director
Patrick Walsh
President/Chief Executive Officer/Director
Nikhil Lalwani
Chief Financial Officer/Vice President - Finance
Stephen Carey
Senior Vice President/Director of Sales
Robert Schrepfer
Senior Vice President
Ori Gutwerg
Senior Vice President
James Marken
General Manager
Davinder Singh
Other
Christopher Mutz
Independent Director
Robert Brown
Independent Director
Thomas Haughey
Independent Director
David Nash
Independent Director
Thomas Penn
Independent Director
Antonio Pera
Independent Director
Jeanne Thoma
No Data
  • All
  • Financials
  • Insiders
More
About ANIP
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Webull offers kinds of ANI Pharmaceuticals Inc stock information, including NASDAQ:ANIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIP stock methods without spending real money on the virtual paper trading platform.